Seer Appoints Nicolas Roelofs to Its Board of Directors
Seer Appoints Nicolas Roelofs to Its Board of Directors
Dr. Roelofs previously served as the President of the Life Sciences Group at Agilent Technologies, Group Operations Officer for the Life Sciences Division of Bio-Rad Inc, and Chief Operating Officer at Stratagene Inc. He has previously served on the boards of several public and private companies including Olink Holding AB. Dr. Roelofs currently serves as chairman of Sengenics Corporation LLC, a board member of Velsera, LGC Group, and an advisory board member of 908 Devices Inc.REDWOOD CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Dr. Nicolas Roelofs to serve on its Board of Directors.
加利福尼亞州紅木城，2024年8月14日，全球新聞通訊社——Seer（納斯達克股票代碼：SEER），一家領先的生命科學公司，致力於商業化一種顛覆性的蛋白質組學新平台，今日宣佈任命Nicolas Roelofs博士擔任其董事會成員。
"Nick is a fantastic addition to our board, bringing over 35 years of broad operational and advisory experience with leading healthcare, life science tools, and diagnostics companies," said Omid Farokhzad, Chair and CEO of Seer. "His extensive experience and insights will be valuable as we advance our mission of opening up a new gateway to the proteome."
「Nick是我們董事會的一名出色成員，他在領先的醫療保健、生命科學工具和診斷公司擁有超過35年的廣泛操作和諮詢經驗，」Seer的主席兼首席執行官Omid Farokhzad表示。「他豐富的經驗和洞見將是寶貴的，因爲在推進我們開啓蛋白質組新門戶的使命時，這將會有所幫助。」
"I'm excited to work with the Seer team and leverage my experience in the life science tools industry to drive their next phase of growth," said Dr. Roelofs. "Seer uniquely enables deep, unbiased proteomic analysis at a scale, speed, and robustness previously not possible, and I believe they are at the leading edge of the expanding proteomics market. I look forward to sharing my insights and experience to help accelerate the adoption of the Proteograph Product Suite and transform our understanding of the proteome."
「我很興奮能與Seer團隊合作，利用我在生命科學工具行業的經驗來推動他們的下一個成長階段，」Roelofs博士說。「Seer在規模、速度和健壯性上實現了深入、無偏見的蛋白質組分析，是先前不可能達到的，我相信他們是擴展蛋白質組學市場的領軍者。我期待分享我的見解和經驗，幫助加速Proteograph產品套件的採用，改變我們對蛋白質組的理解。」
Dr. Roelofs previously served as the President of the Life Sciences Group at Agilent Technologies, Group Operations Officer for the Life Sciences Division of Bio-Rad Inc, and Chief Operating Officer at Stratagene Inc. He has previously served on the boards of several public and private companies including Olink Holding AB. Dr. Roelofs currently serves as chairman of Sengenics Corporation LLC, a board member of Velsera, LGC Group, and an advisory board member of 908 Devices Inc.
Roelofs博士曾擔任安捷倫科技生命科學集團總裁、Bio-Rad Inc生命科學部門的集團運營主管以及Stratagene Inc的首席運營官。他曾在多家公共和私營公司的董事會任職，包括Olink Holding Ab。Roelofs博士目前擔任Sengenics Corporation LLC主席，Velsera和LGC Group董事會成員以及908 Devices Inc諮詢委員會成員。
Dr. Roelofs holds a doctorate in organic chemistry from University of Nevada, Reno, a master's degree in organic chemistry from Iowa State University, and a bachelor's degree in chemistry, biology, and German from Simpson College.
Roelofs博士擁有內華達大學有機化學博士學位、愛荷華州立大學有機化學碩士學位以及辛普森學院的化學、生物學和德語學士學位。
About Seer
關於Seer公司 Seer是一家生命科學公司，正在開發開啓蛋白質組學新大門的變革性產品。 Seer的Proteograph產品套件是一個集成解決方案，包括專有的工程納米顆粒、耗材、自動化儀器和軟件，在幾個小時內進行深入、無偏差的蛋白質組學分析。Seer將Proteograph的工作流程設計爲高效而易於使用，利用廣泛採用的實驗室儀器，提供一種可分散的解決方案，幾乎可以被任何實驗室應用。Seer的Proteograph產品套件僅供研究使用，不適用於診斷程序。有關更多信息，請訪問www.seer.bio。
Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer's Proteograph Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer's Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit .
Seer是一家生命科學公司，正在開發具有變革性的產品，爲蛋白質組提供了新的通道。Seer的Proteograph產品套件是一個集成解決方案，包括專有的特製納米粒子、消耗品、自動化儀器和軟件，可在幾小時內以規模化的方式進行深入、無偏見的蛋白質組學分析。Seer使Proteograph工作流程高效且易於使用，利用廣泛採用的實驗室儀器，提供了一個分散式解決方案，幾乎可以被任何實驗室採納。Seer的Proteograph產品套件僅用於研究，不適用於診斷程序。欲了解更多信息，請訪問。
Investor Contact:
Carrie Mendivil
investor@seer.bio
投資者聯繫人：
Carrie Mendivil
investor@seer.bio
Media Contact:
Patrick Schmidt
pr@seer.bio
媒體聯繫人：
Patrick Schmidt
pr@seer.bio
A photo accompanying this announcement is available at
此公告附帶的照片
譯文內容由第三人軟體翻譯。
